|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM346954940 |
003 |
DE-627 |
005 |
20231226032701.0 |
007 |
cr uuu---uuuuu |
008 |
231226s2022 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1016/j.clim.2022.109131
|2 doi
|
028 |
5 |
2 |
|a pubmed24n1156.xml
|
035 |
|
|
|a (DE-627)NLM346954940
|
035 |
|
|
|a (NLM)36179983
|
035 |
|
|
|a (PII)S1521-6616(22)00212-1
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Jamee, Mahnaz
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Clinical, immunological, molecular and therapeutic findings in monogenic immune dysregulation diseases
|b Middle East and North Africa registry
|
264 |
|
1 |
|c 2022
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 12.10.2022
|
500 |
|
|
|a Date Revised 07.04.2023
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
|
520 |
|
|
|a Monogenic immune dysregulation diseases (MIDD) are caused by defective immunotolerance. This study was designed to increase knowledge on the prevalence and spectrum of MIDDs, genetic patterns, and outcomes in Middle East and North Africa (MENA). MIDD patients from 11 MENA countries (Iran, Turkey, Kuwait, Oman, Algeria, Egypt, United Arab Emirates, Tunisia, Jordan, Qatar, and Azerbaijan) were retrospectively evaluated. 343 MIDD patients (58% males and 42% female) at a median (IQR) age of 101 (42-192) months were enrolled. The most common defective genes were LRBA (23.9%), LYST (8.2%), and RAB27A (7.9%). The most prevalent initial and overall manifestations were infections (32.2% and 75.1%), autoimmunity (18.6% and 41%), and organomegaly (13.3% and 53.8%), respectively. Treatments included immunoglobulin replacement therapy (53%), hematopoietic stem cell transplantation (HSCT) (14.3%), immunosuppressives (36.7%), and surgery (3.5%). Twenty-nine (59.2%) patients survived HSCT. Along with infectious complications, autoimmunity and organomegaly may be the initial or predominant manifestations of MIDD
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
4 |
|a Autoimmune disorders
|
650 |
|
4 |
|a Genetic
|
650 |
|
4 |
|a Immune dysregulation
|
650 |
|
4 |
|a Inborn errors of immunity
|
650 |
|
4 |
|a Lymphoproliferation
|
650 |
|
4 |
|a Primary immunodeficiency
|
650 |
|
7 |
|a Adaptor Proteins, Signal Transducing
|2 NLM
|
650 |
|
7 |
|a LYST protein, human
|2 NLM
|
650 |
|
7 |
|a Vesicular Transport Proteins
|2 NLM
|
650 |
|
7 |
|a rab27 GTP-Binding Proteins
|2 NLM
|
650 |
|
7 |
|a LRBA protein, human
|2 NLM
|
650 |
|
7 |
|a EC 2.7.10.-
|2 NLM
|
650 |
|
7 |
|a RAB27A protein, human
|2 NLM
|
650 |
|
7 |
|a EC 3.6.1.-.
|2 NLM
|
700 |
1 |
|
|a Azizi, Gholamreza
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Baris, Safa
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Karakoc-Aydiner, Elif
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ozen, Ahmet
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Kiliç, Sara Ş
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Kose, Hulya
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Chavoshzadeh, Zahra
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Mahdaviani, Seyed Alireza
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Momen, Tooba
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Shamsian, Bibi Shahin
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Fallahi, Mazdak
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Sharafian, Samin
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Gülez, Nesrin
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Aygun, Ayşe
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Karaca, Neslihan Edeer
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Kutukculer, Necil
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Al Sukait, Nashat
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Al Farsi, Tariq
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Al-Tamemi, Salem
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Khalifa, Nisreen
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Shereen, Reda
|e verfasserin
|4 aut
|
700 |
1 |
|
|a El-Ghoneimy, Dalia
|e verfasserin
|4 aut
|
700 |
1 |
|
|a El-Owaidy, Rasha
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Radwan, Nesrine
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Alzyoud, Raed
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Barbouche, Mohamed-Ridha
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ben-Mustapha, Imen
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Mekki, Najla
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Rais, Afef
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Boukari, Rachida
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Belbouab, Reda
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Djenouhat, Kamel
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Tahiat, Azzeddine
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Touri, Souad
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Elghazali, Gehad
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Al-Hammadi, Suleiman
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Shendi, Hiba Mohammed
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Alkuwaiti, Amna
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Belaid, Brahim
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Djidjik, Reda
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Artac, Hasibe
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Adeli, Mehdi
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Sobh, Ali
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Elnagdy, Marwa H
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Bahgat, Sara A
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Nasrullayeva, Gulnara
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Chou, Janet
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Rezaei, Nima
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Al-Herz, Waleed
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Geha, Raif S
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Abolhassani, Hassan
|e verfasserin
|4 aut
|
700 |
0 |
|
|a MENA-I. E. I. Study Group
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Rasouli, Seyed Erfan
|e investigator
|4 oth
|
700 |
1 |
|
|a Esmaeili, Marzie
|e investigator
|4 oth
|
700 |
1 |
|
|a Yazdani, Reza
|e investigator
|4 oth
|
700 |
1 |
|
|a Delavari, Samaneh
|e investigator
|4 oth
|
700 |
1 |
|
|a Tavakol, Marzieh
|e investigator
|4 oth
|
700 |
1 |
|
|a Sadri, Homa
|e investigator
|4 oth
|
700 |
1 |
|
|a Karimi, Abdollah
|e investigator
|4 oth
|
700 |
1 |
|
|a Shiari, Reza
|e investigator
|4 oth
|
700 |
1 |
|
|a Alavi, Samin
|e investigator
|4 oth
|
700 |
1 |
|
|a Babaie, Delara
|e investigator
|4 oth
|
700 |
1 |
|
|a Eshghi, Peyman
|e investigator
|4 oth
|
700 |
1 |
|
|a Armin, Shahnaz
|e investigator
|4 oth
|
700 |
1 |
|
|a Vosughimotlagh, Ahmad
|e investigator
|4 oth
|
700 |
1 |
|
|a Eltan, Sevgi Bilgic
|e investigator
|4 oth
|
700 |
1 |
|
|a Babayeva, Royala
|e investigator
|4 oth
|
700 |
1 |
|
|a Sefer, Asena Pinar
|e investigator
|4 oth
|
700 |
1 |
|
|a Kolukisa, Burcu
|e investigator
|4 oth
|
700 |
1 |
|
|a Gungoren, Ezgi Yalcin
|e investigator
|4 oth
|
700 |
1 |
|
|a Altunbas, Melek Yorgun
|e investigator
|4 oth
|
700 |
1 |
|
|a Mammadova, Vafa
|e investigator
|4 oth
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 244(2022) vom: 01. Nov., Seite 109131
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:244
|g year:2022
|g day:01
|g month:11
|g pages:109131
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.109131
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 244
|j 2022
|b 01
|c 11
|h 109131
|